Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMMX
stocks logo

IMMX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.190
+26.67%
--
--
-0.180
+20%
--
--
-0.180
-18.18%
Estimates Revision
The market is revising No Change the revenue expectations for Immix Biopharma, Inc. (IMMX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 125.12%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+125.12%
In Past 3 Month
Wall Street analysts forecast IMMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IMMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.840
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 4.840
sliders
Low
8.00
Averages
8.00
High
8.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$7 -> $8
2025-09-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $8
2025-09-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Immix Biopharma to $8 from $7 and keeps a Buy rating on the shares after the company received a strategic investment from Goose Capital and former Tanox CEO Dr. Nancy Chang. The capital provides for an operational runway into Q2 of 2026 for Immix, the analyst tells investors in a research note.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$7
2025-02-10
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$7
2025-02-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$7
2025-01-06
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$7
2025-01-06
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immix Biopharma Inc (IMMX.O) is -6.54, compared to its 5-year average forward P/E of -3.71. For a more detailed relative valuation and DCF analysis to assess Immix Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.71
Current PE
-6.54
Overvalued PE
-1.90
Undervalued PE
-5.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.14
Undervalued EV/EBITDA
-4.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.50
Current PS
0.00
Overvalued PS
26.99
Undervalued PS
-15.99
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

IMMX News & Events

Events Timeline

(ET)
2025-11-12
08:46:31
Immix Biopharma names Grabow as Chief Commercial Officer
select
2025-09-11 (ET)
2025-09-11
09:32:05
Nancy Chang Joins the Board of Directors at Immix Biopharma
select
2025-09-08 (ET)
2025-09-08
16:19:10
Immix Biopharma Secures Strategic Funding from Goose Capital
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-12Newsfilter
Immix Biopharma Names Chief Commercial Officer to Lead NXC-201 Launch

  • Appointment of Michael Grabow: Immix Biopharma has appointed Michael Grabow, a former senior commercial leader at Chimerix, as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201 for relapsed/refractory AL Amyloidosis.

  • NXC-201 Overview: NXC-201 is a CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis, a serious blood disease with no current FDA-approved therapies, and has received both Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation from the FDA.

  • Market Potential: The market for AL Amyloidosis treatments is projected to grow from $3.6 billion in 2017 to $6 billion by 2025, with an estimated 37,270 patients in the U.S. suffering from relapsed/refractory AL Amyloidosis by 2025.

  • Clinical Significance: The CEO of Immix Biopharma emphasized the potential of NXC-201 to transform the standard of care for AL Amyloidosis, highlighting its promising clinical results and the urgent need for effective therapies in this area.

[object Object]
Preview
5.0
11-12SeekingAlpha
Immix Biopharma names Michael Grabow as chief commercial officer to lead NXC-201 launch efforts.

  • New Appointment: Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to oversee the commercialization and launch of NXC-201 for relapsed/refractory AL Amyloidosis.

  • Previous Experience: Before joining Immix, Grabow was Head of Commercial Operations at Chimerix, where he successfully led the Go-To-Market Strategy and launch of the orphan drug MODEYSO.

  • Stock Performance: Immix Biopharma's stock is down 1.54% in premarket trading, currently priced at $3.18.

  • Additional Information: The article references Seeking Alpha’s Quant Rating on Immix Biopharma and provides links to historical earnings data and financial information for the company.

[object Object]
Preview
4.0
09-12Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Immix Biopharma, Increases Price Target to $8

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immix Biopharma Inc (IMMX) stock price today?

The current price of IMMX is 4.84 USD — it has increased 16.63 % in the last trading day.

arrow icon

What is Immix Biopharma Inc (IMMX)'s business?

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

arrow icon

What is the price predicton of IMMX Stock?

Wall Street analysts forecast IMMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immix Biopharma Inc (IMMX)'s revenue for the last quarter?

Immix Biopharma Inc revenue for the last quarter amounts to -7.66M USD, increased 3.62 % YoY.

arrow icon

What is Immix Biopharma Inc (IMMX)'s earnings per share (EPS) for the last quarter?

Immix Biopharma Inc. EPS for the last quarter amounts to -6278232.00 USD, increased 45.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immix Biopharma Inc (IMMX)'s fundamentals?

The market is revising No Change the revenue expectations for Immix Biopharma, Inc. (IMMX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 125.12%.
arrow icon

How many employees does Immix Biopharma Inc (IMMX). have?

Immix Biopharma Inc (IMMX) has 18 emplpoyees as of December 05 2025.

arrow icon

What is Immix Biopharma Inc (IMMX) market cap?

Today IMMX has the market capitalization of 162.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free